Non-alcoholic fatty liver disease (NAFLD), the most common liver disease worldwide, is increasing in prevalence and is currently estimated to affect approximately one-quarter of the general population.
Non-alcoholic fatty liver disease (NAFLD), the most common liver disease worldwide, is increasing in prevalence and is currently estimated to affect approximately one-quarter of the general population. A new study published in the journal Hepatology reveals the clinical and economic burden of NAFLD in the United States and Europe. The findings will help clinicians and policy makers develop strategies to deal with this serious chronic disease.
NAFLD, which is characterized by the build up of extra fat in liver cells, is associated with obesity and diabetes, and it occurs with minimal or no symptom until the disease is advanced. When Zobair Younossi, MD, MPH, of Inova Fairfax Hospital in Virginia, and his colleagues constructed models to assess the potential burden of NAFLD, they estimated that there are 64 million individuals with the disease in the United States and 52 million in the four European countries examined (Germany, France, Italy, and the United Kingdom). Annual direct medical costs were estimated to be approximately $103 billion ($1163 per patient) in the United States and € 35 billion (from € 354 to € 1163 per patient) in the four European countries. The economic burden of NAFLD would be even higher when including societal costs and indirect costs.
“Given the growing epidemic of obesity, diabetes, and NAFLD, this study brings to the attention of policymakers, providers, pharmaceutical companies, payers, and patients the critical importance of understanding NAFLD and establishing a policy for prevention, early detection, and effective therapy,” said Dr. Younossi. “This requires a multi-faceted national and possibly international policy to deal with this common, debilitating, and expensive liver disease.”
Additional Information:
Full Citation: “The Economic and Clinical Burden of Non-alcoholic Fatty Liver Disease (NAFLD) in the United States and Europe.” Zobair M. Younossi, Deirdre Blissett, Robert Blissett, Linda Henry, Maria Stepanova, Youssef Younossi, Andrei Racila, Sharon Hunt, and Rachel Beckerman. Hepatology; Published Online: September 27, 2016 (DOI: 10.1002/hep.28785).
Link to study: http://doi.wiley.com/10.1002/hep.28785
Author Contact: Deena Hallaji, at Deena.Hallaji@inova.org.
About the Journal
Hepatology is the premier publication in the field of liver disease, publishing original, peer-reviewed articles concerning all aspects of liver structure, function and disease. Each month, the distinguished Editorial Board monitors and selects only the best articles on subjects such as immunology, chronic hepatitis, viral hepatitis, cirrhosis, genetic and metabolic liver diseases and their complications, liver cancer, and drug metabolism. Hepatology is published on is published by Wiley on behalf of the American Association for the Study of Liver Diseases (AASLD). For more information, please visit http://wileyonlinelibrary.com/journal/hep.
About Wiley
Wiley is a global provider of knowledge and knowledge-enabled services that improve outcomes in areas of research, professional practice and education. Through the Research segment, the Company provides digital and print scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising. The Professional Development segment provides digital and print books, online assessment and training services, and test prep and certification. In Education, Wiley provides education solutions including online program management services for higher education institutions and course management tools for instructors and students, as well as print and digital content. The Company's website can be accessed at www.wiley.com.
Dawn Peters-
+1 781-388-8408
sciencenewsroom@wiley.com